Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Arch Mal Coeur Vaiss ; 98 Spec No 4: 31-54, 2005 Oct.
Article in French | MEDLINE | ID: mdl-16294557

ABSTRACT

Coronary arteries are the most frequent location of atherosclerosis. Coronary artery disease is the first cause of death related to atherothrombosis. In addition, patients with a prior history of acute coronary syndromes exhibit a 10% annual risk of recurrence. Although there seems to be a close correlation between the extension of CAD and the severity of atherosclerotic lesions in extra coronary arterial beds, the prevalence of these extracoronary asymptomatic lesions depends on their location. Hence, the prevalence of renal artery disease defined as stenosis > or = 50% or of peripheral artery disease defined as an ABI < 0.9 is estimated to be 20% up to 30%, whereas the prevalence of both carotid artery disease defined as stenosis > or = 70% or aortic aneurysm is estimated to be 5%. Conversely, the annual absolute risk of stroke among CAD patients is estimated at 1% while it remains unknown for vascular events related to PAD or aortic lesions. These data suggest that a systematic screening for asymptomatic extracoronary atherosclerotic lesions among CAD patients cannot be justified without a better knowledge of the prevalence of these lesions. In addition, the identification of the predicting factors for the presence and the development of these asymptomatic lesions is warranted. Finally, the potential benefit in terms of therapeutic intervention of such screening needs to be evaluated. These important issues warrant further clinical studies with appropriate design.


Subject(s)
Coronary Artery Disease/epidemiology , Coronary Disease/physiopathology , Coronary Artery Disease/physiopathology , Female , Humans , Male , Prevalence , Risk Factors
2.
Circulation ; 108(4): 391-4, 2003 Jul 29.
Article in English | MEDLINE | ID: mdl-12860898

ABSTRACT

BACKGROUND: A few studies have suggested that von Willebrand factor (vWF) or plasminogen activator inhibitor-1 (PAI-1) can be associated with outcomes of acute coronary syndromes. The present study was designed to assess the acute release of these markers in ST-segment elevation myocardial infarction (STEMI) and their relations to death. METHODS AND RESULTS: In 153 consecutive patients with STEMI, vWF and PAI-1 antigens were measured on admission (H0) and 24 hours later (H24). At 30 days, the death rate was 7.2%. Heart failure (Killip stage > or =3) on admission was present in 13.7% of patients. The acute release of PAI-1 (H24-H0, in ng/mL) and of vWF (H24-H0, in %) was dramatically higher in patients who died than in those who survived (46.9+/-26.3 versus -0.6+/-2.8 ng/mL, P=0.0001 and 65.8+/-20.0% versus 10.0+/-5.1%, P=0.004 for PAI-1 and vWF, respectively) and in patients developing heart failure compared with those without (24.8+/-10.1 versus -1.1+/-3.3 ng/mL, P=0.004 and 47.3+/-11.0% versus 8.1+/-5.6%, P=0.005 for PAI-1 and vWF, respectively). The release of PAI-1 correlated weakly with the left ventricular ejection fraction (R=-0.195, P=0.01) and the peak of troponin (R=0.149, P=0.045). Postangioplasty TIMI-3 flow and the acute release of PAI-1 were the only 2 independent predictors of death at 30 days. CONCLUSIONS: The acute release of vWF and PAI-1 over the first 24 hours of STEMI is associated with death and heart failure. The acute rise of PAI-1 is also a strong independent predictor of death at 30 days.


Subject(s)
Electrocardiography , Myocardial Infarction/blood , Myocardial Infarction/mortality , Plasminogen Activator Inhibitor 1/blood , Aged , Aged, 80 and over , Angioplasty, Balloon, Coronary , Biomarkers , Female , Follow-Up Studies , Heart Failure/blood , Heart Failure/etiology , Heart Failure/mortality , Humans , Male , Middle Aged , Myocardial Infarction/diagnosis , Myocardial Infarction/therapy , Predictive Value of Tests , Risk Assessment , Stents , Stroke Volume , Survival Rate , Troponin/blood , von Willebrand Factor/analysis
3.
Ann Cardiol Angeiol (Paris) ; 52 Suppl 1: 1s-9s, 2003 Dec.
Article in French | MEDLINE | ID: mdl-14752916

ABSTRACT

Antiplatelet therapy is a cornerstone in the medical management of acute coronary syndromes. Three classes of antiplatelet drugs are available in this setting: acetylsalicylic acid, thienopyridines, and glycoprotein IIb/IIIa antagonists. During the last ten years, numerous clinical trials have been conducted in large populations of patients suffering from acute coronary syndromes. Further investigations are in progress. In the light of these results, the respective roles of the different antiplatelet drugs have been more precisely defined, in terms of class preference as well as in terms of the combination of several antiplatelet drugs and of antiplatelet drugs with other therapies, including non fractionated--or low molecular weight--heparin and non-invasive or invasive revascularisation procedures. In the present article, we review the results of the major published or non published trials that addressed the role of glycoprotein IIb/IIIa antagonists in the management of acute coronary syndromes. Based on these results, the current therapeutic guidelines for clinical practice issued by the American and European cardiology societies are given in the conclusion, with their level of evidence.


Subject(s)
Coronary Disease/therapy , Platelet Aggregation Inhibitors/therapeutic use , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Ticlopidine/analogs & derivatives , Acute Disease , Angioplasty, Balloon, Coronary/methods , Clinical Trials as Topic , Clopidogrel , Drug Therapy, Combination , Humans , Myocardial Revascularization , Ticlopidine/therapeutic use
4.
Arch Mal Coeur Vaiss ; 95(10): 951-4, 2002 Oct.
Article in French | MEDLINE | ID: mdl-12462907

ABSTRACT

We report the case of a patient with a past history of coronary atherosclerosis treated with primary angioplasty 5 hours following an inferior myocardial infarction. Echocardiography performed during the procedure revealed a mediastinal tumour invading the tricuspid, responsible for the occlusion of the right coronary. Infarction due to tumour compression is a rare presentation of mediastinal tumour. Diagnosis relies on echocardiographic, CT or magnetic resonance imaging. The prognosis is linked to the tumour pathology.


Subject(s)
Heart Neoplasms/diagnostic imaging , Mediastinal Neoplasms/diagnostic imaging , Myocardial Infarction/diagnostic imaging , Tricuspid Valve/diagnostic imaging , Coronary Artery Disease/complications , Diagnosis, Differential , Echocardiography , Heart Neoplasms/complications , Heart Neoplasms/pathology , Humans , Male , Mediastinal Neoplasms/complications , Mediastinal Neoplasms/pathology , Middle Aged , Myocardial Infarction/etiology , Myocardial Infarction/therapy , Prognosis , Tricuspid Valve/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...